



Estimate the potential financial impact of choosing Launch My Health to address metabolic dysfunction across your employee population with our Digital Suite plus Launch LIVE! webinars.
*Total Population Expected Engagement Rate is applied to the estimated population with metabolic dysfunction. This determines the number of expected participants used in the cost avoidance model.
**Roughly 88% to 93% of American adults exhibit at least one specific marker of metabolic dysfunction. The model estimates potential medical and productivity cost avoidance associated with reducing progression of metabolic disease, including type 2 diabetes, and improving obesity-related health risk. Economic assumptions are informed by published CDC diabetes prevention and obesity-cost data.
***Estimates are directional and are not a guarantee of savings. Actual results will vary based on population risk, participation, clinical outcomes, benefit design, utilization, healthcare costs and other factors.
Healthcare costs continue to rise, driven by specialty medications, hospitalizations and chronic conditions such as diabetes and cardiovascular disease. For HR and benefits leaders, this creates an opportunity to rethink how we define and measure value. Instead of focusing only on traditional cost savings, we should also be measuring cost avoidance.
Cost savings asks: How much did we reduce an existing expense?
Cost avoidance asks: What expensive outcome did we help prevent?


We’ll help you validate assumptions, select the right solution, and prepare a proposal aligned with your population, budget, and goals.